Home Clinical trials For patients Ovary IMGN853-0425

IMGN853-0425

A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression Testing 2 Schedules of Administration for Dose Optimization, With a Separate Cohort to Determine Starting Dose in Patients With Moderate Hepatic Impairment

Open
Trial drug
Mirvetuximab
Grade
High grade
Prior lines
1, 2, 3, 4
Histology
Serous
Platin
Platinum resistant
Phase
II

Treatment

The treatment option in this study is mirvetuximab.
Mirvetuximab is given intravenously.

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.